Insulin resistance and inflammation in the early phase of type 2 diabetes: potential for therapeutic intervention (Q36236500)

12 August 2017

1 reference

title

Insulin resistance and inflammation in the early phase of type 2 diabetes: potential for therapeutic intervention (English)

1 reference

12 August 2017

1 reference

1 reference

Gerit-Holger Schernthaner

series ordinal

1

1 reference

PubMed ID

16112958

12 August 2017

Guntram Schernthaner

series ordinal

2

1 reference

12 August 2017

1 January 2005

1 reference

The Scandinavian journal of clinical & laboratory investigation. Supplementum

12 August 2017

1 reference

12 August 2017

240

1 reference

12 August 2017

30-40

1 reference

Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections

12 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Banting lecture 1988. Role of insulin resistance in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Prevalence of insulin resistance in metabolic disorders: the Bruneck Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Components of the "metabolic syndrome" and incidence of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Fast-food habits, weight gain, and insulin resistance (the CARDIA study): 15-year prospective analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Lilly lecture 2003: the struggle for mastery in insulin action: from triumvirate to republic

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Cardiovascular mortality and morbidity in type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Inflammation: the link between insulin resistance, obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Insulin resistance and chronic cardiovascular inflammatory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Endothelial inflammation in insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Metabolic syndrome: an appraisal of the pro-inflammatory and procoagulant status

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Adipokines: inflammation and the pleiotropic role of white adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Adiponectin and development of type 2 diabetes in the Pima Indian population

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Plasma adiponectin is an independent predictor of type 2 diabetes in Asian indians

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Adiponectin and protection against type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

The pleiotropic functions of peroxisome proliferator-activated receptor gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

The insulin resistance syndrome: definition and dietary approaches to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Physical activity, cardiovascular risk factors, and mortality among Finnish adults with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Adiponectin and beta cell dysfunction in gestational diabetes: pathophysiological implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Progress in the prevention of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Dietary treatment and long-term weight loss and maintenance in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Bariatric surgery: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Impact of Weight Loss on Inflammatory Proteins and Their Association With the Insulin Resistance Syndrome in Morbidly Obese Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Surgery decreases long-term mortality, morbidity, and health care use in morbidly obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Weight loss reduces tissue factor in morbidly obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

Weight loss reduces circulating asymmetrical dimethylarginine concentrations in morbidly obese women

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365510500236119

10.1080/00365510500236119

21 January 2018

Identifiers

DOI

0 references

PubMed ID

16112958

1 reference

PubMed ID

16112958